Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nicotine flux: a new way to gauge how addictive E-Cigarettes are?

NCT ID NCT05430334

Knowledge-focused Sponsor: American University of Beirut Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers at the American University of Beirut are studying whether the rate at which an e-cigarette emits nicotine, called nicotine flux, predicts how much nicotine reaches the body and how users feel. About 142 adult dual users of e-cigarettes and tobacco will use devices with different nicotine concentrations and forms. The team will measure cravings, withdrawal, puffing behavior, and toxicant exposure to see if flux could guide public health rules on e-cigarettes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
e-liquids with different nicotine concentrations and forms (protonated vs free base) in electronic cigarettes
What this could lead to
If nicotine flux predicts nicotine delivery and dependence-related effects, regulators could use it to set product standards that make e-cigarettes less addictive.
What could go wrong
This is a small, short-term lab study in adult dual users, so results may not reflect real-world vaping or youth use. Subjective ratings do not prove addiction risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

142 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be healthy and above 18 years of age * Must be willing to provide informed consent, attend the lab, and abstain from tobacco/nicotine as required (participants will be instructed to abstain from nicotine/tobacco and/or ENDS use for ≥12h) * A dual ENDS and tobacco user who reports daily use of ENDS (≥ 3 mg/ml nicotine) or cigarettes (any frequency) AND someday use (≥ 3 days/week) of ENDS (≥ 3 mg/ml nicotine) or cigarettes (any frequency) for the past 3 months or longer Exclusion Criteria: * History of chronic disease or an uncontrolled psychiatric condition * History of or active cardiovascular disease, low/high blood pressure, seizures, regular use of a prescription medication (except vitamins/birth control) * Past month use of cocaine, opioids, benzodiazepines, or methamphetamines * Individuals who report using marijuana \>15/30 days * Women will be excluded if they are breast-feeding or pregnant * Participants intending to quit tobacco/nicotine use in the next 30 days and referred to cessation treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nicotine addiction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nicotine dependence Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nicotine addiction Nicotine dependence Nicotine vaping

Contacts and locations

Locations

  • American University of Beirut

    Beirut, Beirut, 11-0236, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.